{"id":389,"date":"2018-08-15T12:46:58","date_gmt":"2018-08-15T12:46:58","guid":{"rendered":"https:\/\/credevo.com\/s\/?p=389"},"modified":"2021-05-02T16:17:27","modified_gmt":"2021-05-02T08:17:27","slug":"diabetic-foot-ulcer","status":"publish","type":"post","link":"https:\/\/credevo.com\/s\/diabetic-foot-ulcer\/","title":{"rendered":"Diabetic Foot Ulcer"},"content":{"rendered":"

Credevo recently conducted clinical trial feasibility in Diabetic foot ulcer and the trial feasibility received overwhelming response from medical centers and sites. Total responses received were more than 1000% of number of sites actually sought for this trial.<\/p>\n

Study details<\/h1>\n

The clinical study was a randomized, comparator-controlled, double-blind, multicenter phase-II trial and it aimed to evaluate the efficacy and safety of study medication in patients with Diabetic Foot Ulcer.<\/p>\n

Sites targeted for this feasibility assessment were medical centers and sites located in United States.<\/p>\n

Diabetic Foot Ulcer<\/h2>\n

A diabetic foot is a foot that exhibits any pathology that results directly from diabetes mellitus or any long-term complications of diabetes mellitus. Diabetic foot ulcer is a major complication of diabetes mellitus and probably the major component of the diabetic foot. It occurs in 15% of people with diabetes, and precedes 84% of all diabetes-related lower-leg amputations.<\/p>\n

Summary of results<\/h1>\n

Feasibility data showed that not only there are many experienced and willing sites in United States for such clinical trial, but, more importantly, these sites actually had a lot of patients possible to be recruited in there.<\/p>\n

The recruitment rate projection obtained from this trial was beyond expectations.<\/p>\n

Due to overwhelming response, the feasibility was closed ahead of time.<\/p>\n

Here are the salient results obtained from this feasibility<\/p>\n